Compare drug alternatives

Stelara® Alternatives

Stelara®

(Ustekinumab)
Stelara
Prescription Only

Stelara is an immunosuppressant medication that targets two inflammatory cytokines, IL-12 and IL-23, which are key contributors to chronic inflammation. For Crohn's disease and ulcerative colitis, Stelara is administered every 8 weeks, and for psoriasis, it is given every 12 weeks. Its most frequently reported side effects are an increased susceptibility to infection, as well as nasopharyngitis, headache, and fatigue.

Stelara is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis.

Skyrizi®

(Risankizumab)
Skyrizi
Prescription Only

Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended dose is 150mg administered every 12 weeks as two subcutaneous injections of 75mg, which patients can learn to self-administer. The most frequently reported side effects are upper respiratory tract infections, headache, and fatigue.

Skyrizi is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, and Crohn’s Disease.

Dosage & Administration

Administration
Subcutaneous injection. Learn more.
Subcutaneous injection. Learn more.
Dosing
45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks for adult Psoriatic Arthritis. Weight-based dosing for pediatric Psoriatic Arthritis
150 mg at Week 0, Week 4, and every 12 weeks thereafter.
Latin Shorthand
45 mg Week 0, 4, then 45 mg q12w
150 mg Week 0, 4 then q12w

Financial Assistance

Copay
$5
$5
Annual Cap
$6,000
Assistance Expiration
End of each calendar year (subject to change or discontinuation without notice)
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

Relevant Resources

Stelara
Skyrizi